Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation

Lorella Pasquinucci, Rita Turnaturi, Lucia Montenegro, Filippo Caraci, Santina Chiechio, Carmela Parenti

Research output: Contribution to journalArticle

Abstract

Development of new analgesics endowed with mu/delta opioid receptor (MOR/DOR) activity represents a promising alternative to MOR selective compounds because of their better therapeutic and tolerability profile. Lately, we have synthetized the MOR/DOR agonist LP2 that showed a long lasting antinociceptive activity in the tail flick test, an acute pain model. Here, we investigate whether LP2 is also effective in the mouse formalin test, a model of inflammatory pain sustained by mechanisms of central sensitization. Moreover, we evaluated a possible peripheral component of LP2 analgesic activity. Different doses of LP2 were tested after either intraperitoneal (i.p.) or intraplantar (i.pl.) administration. LP2 (0.75–1.00 mg/kg, i.p.), dose-dependently, counteracted both phases of the formalin test after i.p. administration. The analgesic activity of LP2 (0.75–1.00 mg/kg) was completely blocked by a pretreatment with the opioid antagonist naloxone (3 mg/kg, i.p.). Differently, the pretreatment with naloxone methiodide (5 mg/kg, i.p.), a peripherally restricted opioid antagonist, completely blocked the lower analgesic dose of LP2 (0.75 mg/kg) but only partially relieved the antinociceptive effects of LP2 at the dose of 1.00 mg/kg, thus revealing a peripheral analgesic component of LP2. I.pl. injections of LP2 (10–20 μg/10 μl) were also performed to investigate a possible effect of LP2 on peripheral nerve terminals. Nociceptive sensitization, which occur both at peripheral and central level, is a fundamental step for pain chronicization, thus LP2 is a promising drug for pain conditions characterized by nociceptive sensitization.

Original languageEnglish
Pages (from-to)97-102
Number of pages6
JournalEuropean Journal of Pharmacology
Volume847
DOIs
Publication statusPublished - Mar 15 2019

Fingerprint

Analgesics
Pain
Narcotic Antagonists
Pain Measurement
Central Nervous System Sensitization
delta Opioid Receptor
mu Opioid Receptor
Acute Pain
Naloxone
Peripheral Nerves
Tail
Injections
Pharmaceutical Preparations
Therapeutics

Keywords

  • Mouse formalin test
  • Multitarget ligands
  • Naloxone
  • Naloxone methiodide
  • Opioid
  • Pain
  • Rotarod

ASJC Scopus subject areas

  • Pharmacology

Cite this

Simultaneous targeting of MOR/DOR : A useful strategy for inflammatory pain modulation. / Pasquinucci, Lorella; Turnaturi, Rita; Montenegro, Lucia; Caraci, Filippo; Chiechio, Santina; Parenti, Carmela.

In: European Journal of Pharmacology, Vol. 847, 15.03.2019, p. 97-102.

Research output: Contribution to journalArticle

Pasquinucci, Lorella ; Turnaturi, Rita ; Montenegro, Lucia ; Caraci, Filippo ; Chiechio, Santina ; Parenti, Carmela. / Simultaneous targeting of MOR/DOR : A useful strategy for inflammatory pain modulation. In: European Journal of Pharmacology. 2019 ; Vol. 847. pp. 97-102.
@article{64a910e400004aeba6bd1744b458d231,
title = "Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation",
abstract = "Development of new analgesics endowed with mu/delta opioid receptor (MOR/DOR) activity represents a promising alternative to MOR selective compounds because of their better therapeutic and tolerability profile. Lately, we have synthetized the MOR/DOR agonist LP2 that showed a long lasting antinociceptive activity in the tail flick test, an acute pain model. Here, we investigate whether LP2 is also effective in the mouse formalin test, a model of inflammatory pain sustained by mechanisms of central sensitization. Moreover, we evaluated a possible peripheral component of LP2 analgesic activity. Different doses of LP2 were tested after either intraperitoneal (i.p.) or intraplantar (i.pl.) administration. LP2 (0.75–1.00 mg/kg, i.p.), dose-dependently, counteracted both phases of the formalin test after i.p. administration. The analgesic activity of LP2 (0.75–1.00 mg/kg) was completely blocked by a pretreatment with the opioid antagonist naloxone (3 mg/kg, i.p.). Differently, the pretreatment with naloxone methiodide (5 mg/kg, i.p.), a peripherally restricted opioid antagonist, completely blocked the lower analgesic dose of LP2 (0.75 mg/kg) but only partially relieved the antinociceptive effects of LP2 at the dose of 1.00 mg/kg, thus revealing a peripheral analgesic component of LP2. I.pl. injections of LP2 (10–20 μg/10 μl) were also performed to investigate a possible effect of LP2 on peripheral nerve terminals. Nociceptive sensitization, which occur both at peripheral and central level, is a fundamental step for pain chronicization, thus LP2 is a promising drug for pain conditions characterized by nociceptive sensitization.",
keywords = "Mouse formalin test, Multitarget ligands, Naloxone, Naloxone methiodide, Opioid, Pain, Rotarod",
author = "Lorella Pasquinucci and Rita Turnaturi and Lucia Montenegro and Filippo Caraci and Santina Chiechio and Carmela Parenti",
year = "2019",
month = "3",
day = "15",
doi = "10.1016/j.ejphar.2019.01.031",
language = "English",
volume = "847",
pages = "97--102",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Simultaneous targeting of MOR/DOR

T2 - A useful strategy for inflammatory pain modulation

AU - Pasquinucci, Lorella

AU - Turnaturi, Rita

AU - Montenegro, Lucia

AU - Caraci, Filippo

AU - Chiechio, Santina

AU - Parenti, Carmela

PY - 2019/3/15

Y1 - 2019/3/15

N2 - Development of new analgesics endowed with mu/delta opioid receptor (MOR/DOR) activity represents a promising alternative to MOR selective compounds because of their better therapeutic and tolerability profile. Lately, we have synthetized the MOR/DOR agonist LP2 that showed a long lasting antinociceptive activity in the tail flick test, an acute pain model. Here, we investigate whether LP2 is also effective in the mouse formalin test, a model of inflammatory pain sustained by mechanisms of central sensitization. Moreover, we evaluated a possible peripheral component of LP2 analgesic activity. Different doses of LP2 were tested after either intraperitoneal (i.p.) or intraplantar (i.pl.) administration. LP2 (0.75–1.00 mg/kg, i.p.), dose-dependently, counteracted both phases of the formalin test after i.p. administration. The analgesic activity of LP2 (0.75–1.00 mg/kg) was completely blocked by a pretreatment with the opioid antagonist naloxone (3 mg/kg, i.p.). Differently, the pretreatment with naloxone methiodide (5 mg/kg, i.p.), a peripherally restricted opioid antagonist, completely blocked the lower analgesic dose of LP2 (0.75 mg/kg) but only partially relieved the antinociceptive effects of LP2 at the dose of 1.00 mg/kg, thus revealing a peripheral analgesic component of LP2. I.pl. injections of LP2 (10–20 μg/10 μl) were also performed to investigate a possible effect of LP2 on peripheral nerve terminals. Nociceptive sensitization, which occur both at peripheral and central level, is a fundamental step for pain chronicization, thus LP2 is a promising drug for pain conditions characterized by nociceptive sensitization.

AB - Development of new analgesics endowed with mu/delta opioid receptor (MOR/DOR) activity represents a promising alternative to MOR selective compounds because of their better therapeutic and tolerability profile. Lately, we have synthetized the MOR/DOR agonist LP2 that showed a long lasting antinociceptive activity in the tail flick test, an acute pain model. Here, we investigate whether LP2 is also effective in the mouse formalin test, a model of inflammatory pain sustained by mechanisms of central sensitization. Moreover, we evaluated a possible peripheral component of LP2 analgesic activity. Different doses of LP2 were tested after either intraperitoneal (i.p.) or intraplantar (i.pl.) administration. LP2 (0.75–1.00 mg/kg, i.p.), dose-dependently, counteracted both phases of the formalin test after i.p. administration. The analgesic activity of LP2 (0.75–1.00 mg/kg) was completely blocked by a pretreatment with the opioid antagonist naloxone (3 mg/kg, i.p.). Differently, the pretreatment with naloxone methiodide (5 mg/kg, i.p.), a peripherally restricted opioid antagonist, completely blocked the lower analgesic dose of LP2 (0.75 mg/kg) but only partially relieved the antinociceptive effects of LP2 at the dose of 1.00 mg/kg, thus revealing a peripheral analgesic component of LP2. I.pl. injections of LP2 (10–20 μg/10 μl) were also performed to investigate a possible effect of LP2 on peripheral nerve terminals. Nociceptive sensitization, which occur both at peripheral and central level, is a fundamental step for pain chronicization, thus LP2 is a promising drug for pain conditions characterized by nociceptive sensitization.

KW - Mouse formalin test

KW - Multitarget ligands

KW - Naloxone

KW - Naloxone methiodide

KW - Opioid

KW - Pain

KW - Rotarod

UR - http://www.scopus.com/inward/record.url?scp=85060755463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060755463&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2019.01.031

DO - 10.1016/j.ejphar.2019.01.031

M3 - Article

AN - SCOPUS:85060755463

VL - 847

SP - 97

EP - 102

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -